Open Access
Open access
volume 7 issue 10

FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis

Yujie Wang 1
Qi Sun 2
Ying Ye 3
Xiaoting Sun 4
SiSi Xie 4
Yuhang Zhan 4
Jian Song 1
Xiaoqin Fan 1
Bin Zhang 1
Ming Yang 1
Lei Lv 5
Kayoko Hosaka 6
Yunlong Yang 4
Guohui Nie 1
Publication typeJournal Article
Publication date2022-04-19
scimago Q1
wos Q1
SJR2.917
CiteScore11.5
Impact factor6.1
ISSN23793708
General Medicine
Abstract
Molecular signaling in the tumor microenvironment (TME) is complex, and crosstalk among various cell compartments in supporting metastasis remains poorly understood. In particular, the role of vascular pericytes, a critical cellular component in the TME, in cancer invasion and metastasis warrants further investigation. Here, we report that an elevation of FGF-2 signaling in samples from patients with nasopharyngeal carcinoma (NPC) and xenograft mouse models promoted NPC metastasis. Mechanistically, tumor cell-derived FGF-2 strongly promoted pericyte proliferation and pericyte-specific expression of an orphan chemokine (C-X-C motif) ligand 14 (CXCL14) via FGFR1/AHR signaling. Gain- and loss-of-function experiments validated that pericyte-derived CXCL14 promoted macrophage recruitment and polarization toward an M2-like phenotype. Genetic knockdown of FGF2 or genetic depletion of tumoral pericytes blocked CXCL14 expression and tumor-associated macrophage (TAM) infiltration. Pharmacological inhibition of TAMs by clodronate liposome treatment resulted in a reduction of FGF-2-induced pulmonary metastasis. Together, these findings shed light on the inflammatory role of tumoral pericytes in promoting TAM-mediated metastasis. We provide mechanistic insight into an FGF-2/FGFR1/pericyte/CXCL14/TAM stromal communication axis in NPC and propose an effective antimetastasis therapy concept by targeting a pericyte-derived inflammation for NPC or FGF-2hi tumors.
Found 
Found 

Top-30

Journals

1
2
3
4
Frontiers in Immunology
4 publications, 7.27%
Cell Death and Disease
2 publications, 3.64%
American Journal of Physiology - Cell Physiology
2 publications, 3.64%
Molecular Cancer
2 publications, 3.64%
Stem Cell Research and Therapy
2 publications, 3.64%
Journal of Experimental and Clinical Cancer Research
2 publications, 3.64%
Discover Oncology
2 publications, 3.64%
Cellular and Molecular Immunology
1 publication, 1.82%
OpenNano
1 publication, 1.82%
Chemical Engineering Journal
1 publication, 1.82%
Cancer Letters
1 publication, 1.82%
Journal of Ethnopharmacology
1 publication, 1.82%
Science Translational Medicine
1 publication, 1.82%
Journal of Hazardous Materials
1 publication, 1.82%
Communications Biology
1 publication, 1.82%
Nature Communications
1 publication, 1.82%
Cell and Bioscience
1 publication, 1.82%
Viruses
1 publication, 1.82%
Experimental Eye Research
1 publication, 1.82%
Medicine (United States)
1 publication, 1.82%
Biochemical Pharmacology
1 publication, 1.82%
Placenta
1 publication, 1.82%
World Journal of Surgical Oncology
1 publication, 1.82%
European Journal of Pharmacology
1 publication, 1.82%
Frontiers in Pharmacology
1 publication, 1.82%
Current Opinion in Endocrine and Metabolic Research
1 publication, 1.82%
Signal Transduction and Targeted Therapy
1 publication, 1.82%
Molecular Biomedicine
1 publication, 1.82%
International Journal of Biological Macromolecules
1 publication, 1.82%
Journal of Translational Medicine
1 publication, 1.82%
1
2
3
4

Publishers

5
10
15
20
25
Springer Nature
22 publications, 40%
Elsevier
17 publications, 30.91%
Frontiers Media S.A.
5 publications, 9.09%
American Physiological Society
2 publications, 3.64%
MDPI
2 publications, 3.64%
Wiley
2 publications, 3.64%
American Association for the Advancement of Science (AAAS)
1 publication, 1.82%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.82%
American Diabetes Association
1 publication, 1.82%
Royal Society of Chemistry (RSC)
1 publication, 1.82%
Public Library of Science (PLoS)
1 publication, 1.82%
5
10
15
20
25
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
55
Share
Cite this
GOST |
Cite this
GOST Copy
Wang Y. et al. FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis // JCI insight. 2022. Vol. 7. No. 10.
GOST all authors (up to 50) Copy
Wang Y., Sun Q., Ye Y., Sun X., Xie S., Zhan Y., Song J., Fan X., Zhang B., Yang M., Lv L., Hosaka K., Yang Y., Nie G. FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis // JCI insight. 2022. Vol. 7. No. 10.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1172/jci.insight.157874
UR - https://doi.org/10.1172/jci.insight.157874
TI - FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis
T2 - JCI insight
AU - Wang, Yujie
AU - Sun, Qi
AU - Ye, Ying
AU - Sun, Xiaoting
AU - Xie, SiSi
AU - Zhan, Yuhang
AU - Song, Jian
AU - Fan, Xiaoqin
AU - Zhang, Bin
AU - Yang, Ming
AU - Lv, Lei
AU - Hosaka, Kayoko
AU - Yang, Yunlong
AU - Nie, Guohui
PY - 2022
DA - 2022/04/19
PB - American Society for Clinical Investigation
IS - 10
VL - 7
PMID - 35439170
SN - 2379-3708
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Wang,
author = {Yujie Wang and Qi Sun and Ying Ye and Xiaoting Sun and SiSi Xie and Yuhang Zhan and Jian Song and Xiaoqin Fan and Bin Zhang and Ming Yang and Lei Lv and Kayoko Hosaka and Yunlong Yang and Guohui Nie},
title = {FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis},
journal = {JCI insight},
year = {2022},
volume = {7},
publisher = {American Society for Clinical Investigation},
month = {apr},
url = {https://doi.org/10.1172/jci.insight.157874},
number = {10},
doi = {10.1172/jci.insight.157874}
}